INJECTABLE TREATMENTS |
Anteis joins the coveted scope of FDA-approved manufacturers
that the Food and Drug Administration (FDA) had approved the US marketing authorisation for the Belotero Balance® gel. This range of biofermentation
O
hyaluronic acid-based intradermal filler gels is the result of the partnership between the Swiss company Anteis and Merz Aesthetics, Inc. The Belotero Balance gel is
manufactured using a dynamic cross-linking process developed and patented by Anteis. Belotero Balance has been distributed in the UK, Germany, Italy, Russia, Austria and Switzerland since 2004. This medical treatment is also authorised and distributed worldwide by Anteis under the name Esthélis™ Basic. With the FDA approval of Belotero, the decisively innovative approach, the quality and the serious nature of the Swiss company’s teams have been justly rewarded.
7 years of innovation In 2005, Anteis launched the first
absorbable polydensified, single-phase filler gels, produced from cross-linked biofermentation hyaluronic acid, which would soon lead to its recognition by professionals in aesthetic medicine: Esthélis Basic® and Esthélis Soft®. Esthélis Basic®, known in 'Merz countries' as Belotero Balance, is the first to have benefited from the dynamic cross-linking process. This gives the gel a cohesive polydensified matrix (CPM); that is, a dual-density level, while retaining its single-phase nature.
n 21 November 2011, Anteis SA, in partnership with Merz Aesthetics, Inc., announced
face. It is the only gel in its category to offer the capability both to sculpt and volumise, while being easy to inject.
In addition to fillers, Anteis offers a
range of gels dedicated to the rehydration of the dermis by means of micro-injections: Mesolis® and Mesolis Plus®. These rejuvenation treatments, inspired by mesotherapy, are used to prevent the formation of wrinkles, soften fine lines, and in particular, to rehydrate the skin to restore its full tone and radiance.
The result of this is a gel that is
cohesive, thus avoiding any risk of migration and offering lasting results, and provided with a unique ability to bio-integrate with the dermis in a perfectly homogeneous way, for highly natural results, and minimal side-effects.
The unique properties of Esthélis gels offer new opportunities for practitioners of aesthetic medicine, enabling them to conduct treatment by injecting into the 'hyper-surface', and to develop new filling approaches, such as the 'blanching' technique. Fortélis Extra® has complemented
the range of filler products since 2007. Fortélis Extra®, which was also developed using the dynamic cross- linking process patented by Anteis, has an extra volumising elasticity (EVE), while retaining a unique ability to bio-integrate with the dermis. It is now recognised as an ideal product for enhancing the lips and filling wrinkles and folds. Modélis® is the latest of the gels
22 ❚
developed and distributed by Anteis. This absorbable 'bio-implant', which can be injected into the deep dermis, is used to sculpt the contours of the
Product Portfolio |
prime-journal.com
Awards for the Anteis Injection System Anteis’ extensive research and development programme is focused on the primary ambition of the Swiss company: to provide real added value in the field of aesthetic medicine, ophthalmology and rheumatology.
One of the more recent
innovations of the company illustrates this proactive approach: the Anteis Injection System. This automated electronic
injection system, which can inject all the filler and rehydration gels from the Anteis range, enables practitioners in the field of aesthetics to concentrate solely on the artistic side, without having to manage the restrictions involved with injections (e.g. volume, rate, pressure to be exerted on the plunger). In addition to the considerable ease of use
offered to professionals, the Anteis Injection System leads to a clear reduction of pain, less gel wastage, and a decrease (scientifically proven) in the side-effects caused by manual injections1
. This unprecedented
innovation has already been recognised by a number of international awards. These include the Red Dot Design Award 2010 and the Frost and Sullivan Europe 2011 award. However, Anteis was first awarded the Gusi Peace Prize for its contribution to improving the wellbeing of customers and patients through technological innovation.
The signature of a global leader in the aesthetic medicine Anteis has established itself — in less than 10 years — as one of three leading companies in the world of aesthetic medicine, distributing its products in nearly 100 countries. Its steady R&D investment policy, consideration of the expectations of practitioners and the wellbeing of patients, respect for the concepts of quality and safety, and more, have led to the market authorisation of decisively innovative devices that bring further advances to the practice of aesthetic medicine. Innovations of great beauty, to be followed and adopted.
1. Zenker S. 3D photographic assessment using Canfield Imaging Technology. Body Language 2010; May–June
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76